MPP Global’s eSuite Powers Launch of Canadian Soccer OTT Service, OneSoccer, for MEDIAPRO
WARRINGTON, UK, June 12, 2019 (GLOBE NEWSWIRE) -- MPP Global, the technology company that delivers eSuite, the world’s smartest subscriber management & billing platform, was selected by MEDIAPRO, a leading European broadcaster and multimedia communications group, to power the launch of their new international Canadian soccer OTT service, OneSoccer.
The sports industry is a key focus area for MEDIAPRO, already a prominent global player in rights management for competitions including UEFA Champions League and Liga Brasileirão. In 2019, MEDIAPRO acquired the global media rights to a suite of Canadian soccer properties, including the recently launched Canadian Premier League (CPL). Under a deal with Canadian Soccer Business (CSB), MEDIAPRO will own the rights to every property within the CSB portfolio for the next ten years. This includes the global and domestic rights to the CPL and the Canadian Championship tournament.
Upon obtaining these rights, the group made plans to introduce a new international OTT streaming service dedicated to Canadian soccer. Launched in April 2019, the service, called OneSoccer, will feature thousands of matches over the course of the coming years, including both live and on-demand content.
The new 24/7 live and on-demand streaming channel is available with a 30-day free trial and will carry live coverage of all CPL matches (plus the final). It will also show all home matches of the Canadian national teams, both men’s & women’s, plus all matches of the 2019 Canadian Championship. This involves all professional soccer teams in the country.
The service offers a range of other subscription options to users. Day passes will be available for purchase, while the ‘League Pass’ option offers subscribers the OneSoccer service for the season, with a special rate for CPL club season ticket holders. Additionally, the service will feature weekly news and highlights shows, magazine shows and additional exclusive original programming.
To successfully deliver OneSoccer, MEDIAPRO required a powerful, feature-rich subscriber management and billing platform to continually drive not only subscriber acquisition, but - more importantly - retention. MEDIAPRO leveraged MPP Global's expertise in these areas to further understand how eSuite combats these specific challenges, after which they selected the cloud platform as their solution of choice.
eSuite is specifically designed to monetise digital content and physical products for the Media sector, providing a highly scalable architecture to support both on-demand and live content. The platform is easy to deploy, with an SDK including pre-built user journeys for registration, payment, self-care, product selection and customer service emails. This advanced functionality ensures MEDIAPRO’s OneSoccer OTT service is well-equipped for subscriber acquisition and growth, both on launch and in the future, with eSuite playing an integral role in the project’s success.
Natxo Imaz, CTO, MEDIAPRO, commented: “eSuite has provided us with additional opportunities to generate revenue, increase our speed-to-market and manage the full billing lifecycle of our subscribers more intelligently. Already since go-live, we have obtained more subscribers than initially forecast so early on.
“Implementing eSuite was very much a plug-and-play process for us, in large part due to the extensive nature of the eSuite platform and thanks to its Support Centre, which was an invaluable resource for us to find answers to our questions about the platform. It's not every day we come across documentation as good as MPP Global’s.
“This has probably been the easiest integration we’ve ever had with an external platform. I am confident that with the winning combination of eSuite's intuitive functionality and continued support from MPP Global, OneSoccer will be a success for MEDIAPRO.”
Paul Johnson, CEO and Co-Founder, MPP Global, said: “OneSoccer marks MEDIAPRO’s first foray into the Canadian market, and we’re delighted to have contributed to their milestone.
“The project has been seamless, with implementation delivered in a record time; from kick off to go-live, it was just 46 days, which is a great achievement and testament to the expertise and professionalism of the team here at MPP Global. Our Support Centre and experienced implementation teams played an integral role in how swiftly MEDIAPRO were able to implement eSuite, ensuring minimal overheads and time-to-market for their new OTT service.”
Chris Welsh, VP, TV & Sport, Europe, MPP Global, added: “The OneSoccer platform will use the full suite of modules available in eSuite, including registration, IDM, authentication, entitlement provisioning, subscriber management, payments, billing, subscriber CRM, commerce, reports, dashboards and more.
“Our experience working with Natxo and his skilled development teams has provided us with great confidence that subscriber numbers will continue to rise, especially as we embark on future phases of the OneSoccer launch with MEDIAPRO, rolling out apps on additional platforms.”
Find out more about MPP Global and eSuite: www.mppglobal.com.
For further information, contact:
Paul Rose, Head of Marketing at MPP Global
+44 (0) 844 873 1418
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CEST | Pressemelding
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients
Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CEST | Pressemelding
LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CEST | Pressemelding
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle
iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CEST | Pressemelding
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CEST | Pressemelding
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CEST | Pressemelding
Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi